Preparation of human monoclonal antibodies against a cytomegalovirus glycoprotein complex of 130 and 55 kDa.
Nine human monoclonal antibodies (MAbs) with neutralization activity against cytomegalovirus (CMV) were obtained by screening human MAbs using a CMV glycoprotein complex of 130 and 55 kDa (gp130/55). The gp130/55 antigen was purified by immunoaffinity chromatography and the purified antigen used to detect anti-gp130/55 MAbs in an enzyme-linked immunosorbent assay. Relatively few of the human anti-CMV MAbs were directed against gp130/55 but all showed high neutralization activities to a variety of clinical isolates with titers (ED50 values) ranging from 0.15 to 7.9 micrograms/ml. Six of the nine anti-gp130/55 MAbs required complement for virus neutralization. Such human MAbs may prove to be useful for passive immunotherapy against CMV infection.
Teijin Institute for Biomedical Research, Tokyo, Japan.
T
T
Tomiyama
Y
Y
Matsumoto
T
T
Sugano
S
S
Fujinaga
Y
Y
Masuho
D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000032:analysis; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D009500:Neutralization Tests; D014764:Viral Proteins / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000939:Epitopes; D006023:Glycoproteins; D014764:Viral Proteins